Isolation of a Ceftazidime-Avibactam-Resistant Blakpc-71-positive Klebsiella Pneumoniae Clinical Isolate

Siquan Shen,Qingyu Shi,Renru Han,Yan Guo,Yang,Shi Wu,Dandan Yin,Fupin Hu

DOI: https://doi.org/10.1128/spectrum.01840-21

IF: 3.7

2022-01-01

Microbiology Spectrum

Abstract:Carbapenem-resistant Klebsiella pneumoniae with the characteristics of extensive drug resistance has been increasingly reported worldwide, accompanied by high mortality rates because the available therapeutic regimens for treatment of infections are limited (1). According to data from the China Antimicrobial Surveillance Network, the rates of K. pneumoniae resistance to meropenem and imipenem constantly increased from 2.9% and 3.0%, respectively, in 2005 to 27.1% and 25.5% in 2021 (2). In Europe, carbapenem-resistant K. pneumoniae strains are most widespread in the Mediterranean and Balkan countries, with prevalence rates of 60% in Greece and 40% in Italy (3). Production of Klebsiella pneumoniae carbapenemase (KPC) is the most common mechanism of K. pneumoniae resistance to carbapenems (4), involving almost entirely blaKPC-2 in China (4). Currently, ceftazidime-avibactam is one of the best available therapeutic options for infections caused by such isolates. Several studies reported that ceftazidime-avibactam presents excellent in vitro activity for the effective inhibition of serinecarbapenemase (KPC and OXA-48-like), and it was then endorsed as a first-line drug for the treatment of carbapenem-resistant Enterobacteriaceae (CRE)-related infections in China in 2019. However, following the wide clinical application of ceftazidime-avibactam, K. pneumoniae acquired resistance rapidly. Currently, 98 blaKPC subtypes have been reported in the world (5); all of the novel blaKPC variants reported in China were mutated from blaKPC-2, while those in the United States were mainly from blaKPC-3 (6–9). In this study, we describe the characterization of a ceftazidime-avibactam-resistant blaKPC-71-positive K. pneumoniae clinical isolate. Forty-five days after femoral neck fixation, a 71-year-old female patient had an intermittent fever for more than 1 month, and multidrug-resistant K. pneumoniae was isolated from a sputum sample. The isolate was resistant to expanded-spectrum cephalosporins (ceftazidime and cefepime), imipenem, meropenem, amikacin, ciprofloxacin, and trimethoprim-sulfamethoxazole but was susceptible to ceftazidime-avibactam and tigecycline. Later, the patient was admitted to Huashan Hospital, Fudan University (eastern China), and ceftazidime-avibactam (2.5 g every 8 h) was used for treatment of the infection after her hospitalization. Ceftazidime-avibactamresistant K. pneumoniae HS645 was isolated from sputum after 3 days. The therapeutic regimen was switched to ceftazidime-avibactam (2.5 g every 8 h) plus aztreonam (1 g every 8 h) 3 days later, and K. pneumoniae strain HS826, carrying blaKPC-2, was isolated at the same time; tigecycline (first dose of 100 mg and then continuous infusion of 50 mg every 12 h) was used for the treatment of these two strains. The patient recovered and was discharged 21 days after admission. Identification of the isolate at the species level was carried out using a Vitek mass spectrometer. Antimicrobial susceptibility testing was carried out with the broth microdilution method, and results were interpreted according to the CLSI breakpoints (10). The results indicated that K. pneumoniae HS645 was Editor Jeanette W. P. Teo, National University Hospital Copyright © 2022 Shen et al. This is an openaccess article distributed under the terms of the Creative Commons Attribution 4.0 International license. Address correspondence to Fupin Hu, hufupin@fudan.edu.cn.